ESMO Immuno-Oncology 2022 | Advances in utilizing neoadjuvant immunotherapy in melanoma

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the role of neoadjuvant immunotherapy in melanoma. Findings from the Phase II SWOG S1801 trial (NCT03698019) demonstrated the superiority of neoadjuvant pembrolizumab. Using ctDNA analysis as well as pre- and post-treatment biopsies can guide patients towards better treatment strategies. Multiple clinical trials including the KEYMAKER-U02 (NCT04305054) and MORPHEUS (NCT05116202) will further investigate novel neoadjuvant regimens and treatment markers. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.